
Quarterly report 2024-Q3
added 10-28-2024
Inari Medical Revenue 2011-2026 | NARI
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Inari Medical
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 383 M | 277 M | 140 M | 51.1 M | 6.83 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 383 M | 6.83 M | 172 M |
Quarterly Revenue Inari Medical
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 153 M | 146 M | 143 M | - | 126 M | 119 M | 116 M | - | 96.2 M | 92.7 M | 86.8 M | - | 72.9 M | 63.5 M | 57.4 M | - | 38.7 M | 25.4 M | 27 M | - | 14.2 M | 10.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 153 M | 10.1 M | 81.7 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Align Technology
ALGN
|
4 B | $ 174.53 | -1.3 % | $ 13.1 B | ||
|
Alphatec Holdings
ATEC
|
764 M | $ 11.07 | -5.06 % | $ 1.66 B | ||
|
Bio-Rad Laboratories
BIO
|
2.57 B | $ 277.5 | -1.3 % | $ 7.83 B | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 12.22 | 0.33 % | $ 1.65 B | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.36 | -0.3 % | $ 126 M | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Bruker Corporation
BRKR
|
3.37 B | $ 37.98 | -0.71 % | $ 5.66 K | ||
|
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.6 | -2.45 % | $ 37.3 M | ||
|
Boston Scientific Corporation
BSX
|
20.1 B | $ 61.28 | -2.05 % | $ 90.7 B | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 8.96 | -2.29 % | $ 254 M | ||
|
Electromed
ELMD
|
64 M | $ 24.41 | 0.04 % | $ 206 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
Globus Medical
GMED
|
2.94 B | $ 91.4 | -0.61 % | $ 12.4 B | ||
|
Butterfly Network
BFLY
|
82.1 M | $ 4.15 | 0.24 % | $ 878 M | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 9.88 | 0.3 % | $ 354 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Inogen
INGN
|
349 M | $ 6.66 | -0.15 % | $ 177 M | ||
|
Inspire Medical Systems
INSP
|
912 M | $ 56.69 | 6.2 % | $ 1.66 B | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 36.93 | 0.93 % | $ 1.15 B | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.04 | 0.97 % | $ 17.6 M | ||
|
Integer Holdings Corporation
ITGR
|
1.85 B | $ 86.67 | -0.93 % | $ 3.01 B | ||
|
FONAR Corporation
FONR
|
97.6 M | $ 18.61 | -0.05 % | $ 122 M | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 79.15 | -3.13 % | $ 46.3 B | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 15.94 | -0.44 % | $ 374 M | ||
|
Helius Medical Technologies
HSDT
|
644 K | $ 1.89 | 0.53 % | $ 1.15 M | ||
|
LivaNova PLC
LIVN
|
1.39 B | $ 63.37 | -2.0 % | $ 3.46 B | ||
|
LENSAR
LNSR
|
58.4 M | $ 5.46 | -1.27 % | $ 65.3 M | ||
|
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M |